DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Tech
Author Program NEWCreate Narrative
NOVT logo

Novanta Inc. Stock Price

NasdaqGS:NOVT Community·US$5.0b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 11 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

NOVT Share Price Performance

US$133.14
19.96 (17.64%)
​
US$194.50
Fair Value
US$133.14
19.96 (17.64%)
31.5% undervalued intrinsic discount
US$194.50
Fair Value
Price US$133.14
AnalystConsensusTarget US$194.50
Sat, 22 Aug 26
Fair ValueUS$194.50
Share Pricen/a

NOVT Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$194.5 31.5% undervalued intrinsic discount

Robotics And Healthcare Demand Will Expand Market Opportunities

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
NOVT logo
Novanta
31.5% undervalued intrinsic discount

Robotics And Healthcare Demand Will Expand Market Opportunities

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 22 Aug
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
NOVT logo

NOVT: Future Returns Will Depend On Executing Medical Acquisition And Restructuring Strategy

Fair Value: US$194.5 31.5% undervalued intrinsic discount
5 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

1 Risk
2 Rewards
View Full Analysis

Novanta Inc. Key Details

US$1.0b

Revenue

US$571.0m

Cost of Revenue

US$458.7m

Gross Profit

US$396.9m

Other Expenses

US$61.8m

Earnings

Last Reported Earnings
Jul 03, 2026
Next Reporting Earnings
n/a
1.63
44.54%
6.00%
14.2%
View Full Analysis

About NOVT

Founded
1968
Employees
3000
CEO
Matthijs Glastra
WebsiteView website
www.novanta.com

Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.

Recent NOVT News & Updates

Seeking Alpha • Aug 23

Novanta: A Strong Year So Far, Fully Priced In

Summary Novanta completed the Riverpoint Medical acquisition, enhancing recurring consumables and medical business growth prospects. Q2 sales rose 10% to $266M with 9% organic growth and adjusted EBITDA up 16%, reflecting strong operational performance. Forward guidance projects 2026 sales of $1.135B and adjusted earnings of $3.71 per share, with Riverpoint contributing $0.18-$0.25 EPS in 2027. Despite improved fundamentals and backlog, Novanta trades at a demanding 36-37x forward earnings, keeping risk-reward only modestly improved. Read the full article on Seeking Alpha
User avatar
Narrative Update • Aug 22

NOVT: Future Returns Will Depend On Executing Medical Acquisition And Restructuring Strategy

Analysts have lifted their price target on Novanta to $194.50 from $182, citing updated valuation work after Q2 results and the stock's inclusion on a conviction list as key supports for the new view. Analyst Commentary Recent research updates around Novanta highlight how analysts are thinking about the stock after the latest Q2 results and its inclusion on an analyst conviction list.

Recent updates

No updates

Novanta Inc. Competitors

FLEX logo

Flex

Symbol: NasdaqGS:FLEX
Market cap: US$40.1b
NTAP logo

NetApp

Symbol: NasdaqGS:NTAP
Market cap: US$38.8b
UI logo

Ubiquiti

Symbol: NYSE:UI
Market cap: US$35.7b
P logo

Everpure

Symbol: NYSE:P
Market cap: US$34.7b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide